Literature DB >> 12927781

Identification and characterization of p100HB, a new mutant form of p100/NF-kappa B2.

Emmanuel Derudder1, Arnaud Laferté, Valérie Ferreira, Zohair Mishal, Véronique Baud, Nadine Tarantino, Marie Körner.   

Abstract

P100, which is encoded by NF-kappa B2, inhibits Rel dimers. It can also be processed into p52, one of the DNA binding sub-units of NF-kappa B/Rel factors. Several p100 C-terminal truncations that result from gene rearrangements are associated with lymphomagenesis. Here, we characterized a new p100 mutant that we termed p100HB. It originates from a point-mutation that generates a premature stop-codon, and thus the protein lacks the last 125 amino acids. We have detected p100HB in several human tumor cell lines. The truncated protein is mainly unprocessed, and although it still binds Rel dimers, it has reduced inhibitory potency compared to p100 and translocates into the nucleus. Thus, p100HB may be associated with deregulated NF-kappa B/Rel functions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927781     DOI: 10.1016/s0006-291x(03)01474-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.

Authors:  Ryan C Thompson; Melanie Herscovitch; Ian Zhao; Tyler J Ford; Thomas D Gilmore
Journal:  J Biol Chem       Date:  2010-10-14       Impact factor: 5.157

2.  Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.

Authors:  Zhe Wang; Baochun Zhang; Liqun Yang; Jane Ding; Han-Fei Ding
Journal:  J Biol Chem       Date:  2008-02-15       Impact factor: 5.157

3.  Diabetes-induced atrophy is associated with a muscle-specific alteration in NF-kappaB activation and expression.

Authors:  Bruce C Frier; Earl G Noble; Marius Locke
Journal:  Cell Stress Chaperones       Date:  2008-07-17       Impact factor: 3.667

4.  FYN-TRAF3IP2 induces NF-κB signaling-driven peripheral T cell lymphoma.

Authors:  Christine S Moon; Clara Reglero; Jose R Cortes; S Aidan Quinn; Silvia Alvarez; Junfei Zhao; Wen-Hsuan W Lin; Anisha J Cooke; Francesco Abate; Craig R Soderquist; Claudia Fiñana; Giorgio Inghirami; Elias Campo; Govind Bhagat; Raul Rabadan; Teresa Palomero; Adolfo A Ferrando
Journal:  Nat Cancer       Date:  2021-01-13

5.  NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors.

Authors:  Brian A McCarthy; Liqun Yang; Jane Ding; Mingqiang Ren; William King; Mohammed ElSalanty; Ibrahim Zakhary; Mohamed Sharawy; Hongjuan Cui; Han-Fei Ding
Journal:  BMC Cancer       Date:  2012-05-29       Impact factor: 4.430

6.  A Novel Monoallelic Nonsense Mutation in the NFKB2 Gene Does Not Cause a Clinical Manifestation.

Authors:  Jerzy Kotlinowski; Karolina Bukowska-Strakova; Agnieszka Koppolu; Joanna Kosińska; Natalia Pydyn; Piotr Stawinski; Mateusz Wilamowski; Witold Nowak; Alicja Józkowicz; Jarosław Baran; Rafał Płoski; Jolanta Jura
Journal:  Front Genet       Date:  2019-02-26       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.